Trials / Completed
CompletedNCT05836428
Biomarker Analysis in Post-COVID Patients
Biomarker Analysis in COVID and Post-COVID Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (actual)
- Sponsor
- University Hospital, Bonn · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.
Detailed description
Measurements of neuronal and glial markers in CSF were performed on a SIMOA analyzer (Quanterix) using the Neurology 4-Plex A (Nf-L, Tau, GFAP, UCH-L1) kit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention | no intervention |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2023-04-26
- Completion
- 2023-04-26
- First posted
- 2023-05-01
- Last updated
- 2023-05-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05836428. Inclusion in this directory is not an endorsement.